Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
Pyrazinamide (PZA) is still one of the key drugs used in current therapeutic regimens for tuberculosis (TB). Despite its importance for TB therapy, the mode of action of PZA remains unknown. PZA has to be converted to its active form pyrazinoic acid (POA) by the nicotinamidase PncA and is then excreted by an unknown efflux pump. At acidic conditions, POA is protonated to HPOA and is reabsorbed into the cell where it causes cellular damage. For a long time, it has been thought that PZA/POA has no defined target of action, but recent studies have shown that both PZA and POA have several different targets interfering with diverse biochemical pathways, especially in the NAD(+) and energy metabolism. PZA resistance seems to depend not only on a defective pyrazinamidase but is also rather a result of the interplay of many different enzyme targets and transport mechanisms.
LIONEX Diagnostics and Therapeutics GmbH, Salzdahlumer Straße 196, D-38126, Braunschweig, Germany.
Matthias
M
Stehr
Ayssar A
AA
Elamin
Mahavir
M
Singh
D000995:Antitubercular Agents / Q000627:therapeutic use*; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D009536:Niacinamide / Q000031:analogs & derivatives; D011718:Pyrazinamide / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D009536:Niacinamide; D011718:Pyrazinamide
Mycobacterium tuberculosis; POA; PZA; PZase; drug susceptibility; nicotinamidase; pyrazinamide